Antisense oligonucleotide therapy in cancer

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 118-122

  Stephens, Alick C ^a   Rivers, Rodney P A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antisense oligonucleotide; Cancer; Clinical trials; Target mRNA; Therapeutics

Indexed keywords

AFFINITAC; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CGP 69846A; CISPLATIN; CLUSTERIN; COMPLEMENTARY DNA; DNA; DNA METHYLTRANSFERASE; GENE EXPRESSION MODULATOR 231; GT 1 2040; ISIS 3521; L 3001; L 900003; LIPID; LR 3001; MESSENGER RNA; MG 98; OBLIMERSEN; OGX 011; OGX 133; OL(1)P53; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PEPTIDE; PHOSPHOROTHIOIC ACID; POLYMER; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; RAF PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CELL GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DNA HYBRIDIZATION; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TARGETING; GENE ACTIVITY; GENE SEQUENCE; HUMAN; HUMAN GENOME; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PARTIAL THROMBOPLASTIN TIME; PROSTATE CANCER; PROTEIN INDUCTION; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; SOLID TUMOR; THROMBOCYTOPENIA;

APOPTOSIS; CLUSTERIN; GENES, BCL-2; GLYCOPROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C;

EID: 0038137440     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA (1978) 75(1):285-288.
2. Gewirtz AM: Oligonucleotide therapeutics: A step forward. J Clin Oncol (2000) 18(9):1809-1811.
3. Matveeva OV, Tsodikov AD, Giddings M, Freier SM, Wyatt JR, Spiridonov AN, Shabalina SA, Gesteland RF, Atkins JF: Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res (2000) 28(15):2862-2865.
4. Dias N, Stein CA: Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm (2002) 54(3):263-269.
5. Jansen B, Zangemeister-Wittke U: Antisense therapy for cancer - the time of truth. Lancet Oncol (2002) 3(11):672-683
6. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg (2001) 121(4):714-722.
7. Yacshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114(6):1133-1142.
8. zu Putlitz J, Yu Q, Burke JM, Wands JR: Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol (1999) 73(7):5381-5387.
9. Katz SM, Tian L, Stepkowski SM, Phan T, Bennett CF, Kahan BD: Effect of ICAM-1/LFA-1 blockade on pancreatic islet allograft survival, function and early cytokine production. Transplant Proc (1997) 29(1-2):748-749.
10. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
11. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science (1998) 281(5381):1322-1326.
12. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 29(6 Suppl 16):15-18.
13. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res (2001) 7(1):14-23.
14. Morris MC, Chaloin L, Heitz F, Divita G: Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol (2000) 11(5):461-466.
15. Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 77:25-79.
16. Lu Y, Low PS: Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev (2002) 54(5):675-693.
17. Tu GC, Cao QN, Zhou F, Israel Y: Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J Biol Chem (1998) 273(39):25125-25131.
18. Matveeva OV, Tsodikov AD, Giddings M, Freier SM, Wyatt JR, Spiridonov AN, Shabalina SA, Gesteland RF, Atkins JF: Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res (2000) 28(15):2862-2865.
19. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. Blood(1996) 88(2):386-401.
20. Agrawal S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta (1999) 1489(1):53-68.
21. Krieg AM, Yi AK, Hartmann G: Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol Ther (1999) 84(2):113-120.
22. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349(9059):1137-1141.
23. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst (1997) 89(14):1027-1036.
24. Yuspa SH, Dlugosz AA, Cheng CK, Denning MF, Tannenbaum T, Glick AB, Weinberg WC: Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol (1994) 103(Suppl 5):90S-95S.
25. Yuen A, Advani R, Fisher G, Halsey J, Lum B, Geary R, Kwoh T, Holmlund J, Dorr A, Sikic BI: A phase I/II trial of ISIS-3521, an antisense inhibitor of protein kinase C-α, combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Am Soc Clin Oncol (2000) 19:Abs 1802.
26. Isis Pharmaceuticals Inc: Isis Pharmaceuticals and Eli Lilly and company announce results of Affinitak phase III clinical trial in non-small cell lung cancer. Press Release (2003) March 17.
27. Howe LR, Leevers SJ, Gomez N, Nakielny S, Cohen P, Marshall CJ: Activation of the MAP kinase pathway by the protein kinase Raf. Cell (1992) 71(2):335-342.
28. Oza AM, Eisenhauer E, Swenerton K: Phase II study of c-Raf kinase antisense oligonucleotide ISIS-5132 in patients with recurrent ovarian cancer. Clin Cancer Res (2000) 6:4572.
29. Isis Pharmaceuticals Inc: Isis Pharmaceuticals reports financial results and highlights for the year 2001. Press Release (2002) February 07.
30. Miyake H, Chi KN, Gleave ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2000) 6(5):1655-1663.
31. OncoGenex Technologies Inc, ISIS Pharmaceuticals Inc: OncoGenex Technologies and Isis Pharmaceuticals achieve alliance milestone: Initiate phase I clinical trial of antisense drug in prostate cancer. Press Release (2002) December 16.
32. MacLeod AR, Rouleau J, Szyf M: Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem (1995) 270(19):11327-11337.
33. Siu LL, Gelmon KA, Moore MJ, Britten CD, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK: A phase I and pharmacokinetic (PK) study of the human DNA methyltransferase (METASE) antisense oligonucleotide MG-98 given as a 21-day continous infusion every 4 weeks. Proc Am Soc Clin Oncol (2000) 19:Abs 733.
34. Barletta C, Pelicci PG, Kenyon LC, Smith SD, Dalla-Favera R: Relationship between the c-myb locus and the 6q-chromosome aberration in leukemias and lymphomas. Science (1987) 235(4792):1064-1067.
35. de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F: BCR-ABL antisense oligonucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advance phase. Blood (1998) 91(9):3156-3162.
36. Miyake H, Pollak M, Gleave M: Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-1 activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res (2000) 60(11):3058-3064.
37. Nickerson T, Miyaki H, Gleave M, Pollak M: Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res (1999) 59(14):3392-3395.
38. Davis H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al: Mutations of the braf gene in human cancer. Nature (2002) 417(6892):949-954.
39. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA et al: BCL-2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell (2002) 109(6):707-718.
40. Krieg AM: The role of CpG motifs in innate immunity. Curr Opin Immunol (2000) 12(1):35-43.
41. Bokarewa MI, Hellstrand K, Tarkowski A: Phosphorothioated oligonucleotides trigger synthesis of human coagulation serine proteases. Thromb Haemost (2002) 88(5):788-793.
42. Pisetsky D, Reich CF: The binding of anti-DNA antibodies to phosphorothioate oligonucleotides in a solid phase immunoassay. Mol Immunol (1998) 35(18):1161-1170.
43. Sharma A, Isenberg D, Diamond B: Studies of human polyclonal and monoclonal antibodies to lupus autoantigens and cross-reactive antigens. Rheumatology (2003) 42(3):453-463.